Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday – TheStreet.com
TheStreet.com |
Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday
TheStreet.com The Oncologic Drugs Advisory Committee will examine the safety of CAR T-cell treatments, an immunotherapy manufactured by Novartis AG (NVS) for treatment of children and young adult leukemia patients who have not responded to traditional treatments. Novartis readies for FDA review of $1 billion CAR-T child cancer hope Novartis dodged deaths from its CAR-T Therapy, but FDA still has safety concerns Novartis' CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory Panel |
